# AlphaGalerkin Valuation Framework

## Overview
Stage-based valuation model for AlphaGalerkin, benchmarked against AI-for-simulation M&A transactions and SBIR-to-acquisition trajectories. The simulation software market commands 10.5x-16.3x revenue multiples — significantly higher than typical SaaS (6-8x).

## Stage-Based Valuation

| Stage | Milestone | Valuation Range | Key Evidence | Dilution |
|-------|-----------|----------------|--------------|----------|
| **Pre-revenue (current)** | Working prototype, TRL 3-4, provisional patents | $1M-$3M | Novelty gap, benchmark results, 3 patent claims | N/A (founder-owned) |
| **Post-SBIR Phase I** | Government validation, published benchmarks | $3M-$8M | $275K+ non-dilutive funding, agency endorsement | 0% (SBIR is non-dilutive) |
| **Post-SBIR Phase II** | Product-market fit, $100K-$500K ARR | $8M-$20M | $1-2M non-dilutive, early commercial traction | 0% (SBIR non-dilutive) |
| **Series A** | $1M+ ARR, enterprise customers | $20M-$60M | Proven product, repeatable sales, team growth | 20-30% equity |
| **Growth / Acquisition** | $5M+ ARR, defensible IP, strategic value | $50M-$200M+ | At 10-20x revenue multiple | Exit event |

## SBIR Non-Dilutive Advantage

SBIR/STTR provides a unique path to significant funding without equity dilution:

| Phase | Funding | Cumulative | Dilution |
|-------|---------|------------|----------|
| AFWERX Phase I | $75K | $75K | 0% |
| Navy Phase I | $250K | $325K | 0% |
| NSF Phase I + TABA | $311K | $636K | 0% |
| DOE Phase I | $250K | $886K | 0% |
| DARPA D2P2 | $1.5M | $2.4M | 0% |
| Navy Phase II | $1.75M | $4.1M | 0% |
| NSF Phase II | $1M | $5.1M | 0% |
| DOE Phase II | $1.5M | $6.6M | 0% |
| **Total Non-Dilutive** | | **$6.6M** | **0%** |

At Series A, the founder retains 100% equity with $6.6M in validated non-dilutive funding — dramatically stronger negotiating position than typical startups.

## Comparable Transactions

| Company | Stage | Valuation/Deal | Revenue Multiple | Relevance |
|---------|-------|---------------|-----------------|-----------|
| PhysicsX | Series B (2024) | ~$1B valuation | N/A (pre-revenue at time) | AI simulation, no MCTS |
| BeyondMath | Seed (2024) | ~$100M implied | N/A (pre-revenue) | FNO-based simulation |
| Hexagon D&E | Acquisition by Cadence | $3.16B | ~14x revenue | Simulation software |
| Beta CAE | Acquisition by Cadence | $1.24B | ~12x revenue | Pre/post-processing for FEA |
| Altair | Acquisition by Siemens | $10B | ~16.3x revenue | Multi-physics simulation |
| Ansys | Acquisition by Synopsys | $35B | ~14.5x revenue | Market leader, simulation |

## Valuation Drivers Specific to AlphaGalerkin

| Driver | Impact | Evidence |
|--------|--------|----------|
| **Verified novelty gap** | High — defensible moat | No published MCTS + Galerkin papers |
| **Provisional patents** (3 claims) | High — IP barrier | `docs/proposals/IP_STRATEGY.md` |
| **Government validation** (SBIR) | High — de-risks technology | Agency endorsement = customer discovery |
| **Revenue multiples** (10-16x) | Very high — simulation premium | M&A transactions 2024-2026 |
| **Strategic acquirer demand** | Very high — active M&A cycle | Cadence, Siemens, Synopsys all acquiring |
| **Zero-shot transfer** | Medium — unique technical capability | MSE 0.000209 (240x better than threshold) |

## Key Risks to Valuation

| Risk | Probability | Mitigation |
|------|------------|------------|
| Competitor publishes MCTS+Galerkin | Low (novelty verified) | File patents + publish strategically |
| SBIR not reauthorized | Low (S.3971 passed House) | Diversify to VC if needed |
| Technical risk (convergence issues) | Medium | LBB stability guard, benchmark suite |
| Single-person team risk | High | Use SBIR to fund first hires |
| Market timing (M&A slowdown) | Medium | SBIR provides runway regardless |

## References
- M&A landscape: `docs/proposals/MA_LANDSCAPE.md`
- IP strategy: `docs/proposals/IP_STRATEGY.md`
- Competitive landscape: `docs/proposals/COMPETITIVE_LANDSCAPE.md`
